Alzamend Neuro, Inc. (ALZN)
D
Pipeline Grade
Financial Position (from SEC Filings)
$2.7M
Cash & Equivalents
$5.3M
Quarterly Burn Rate
2 mo
Est. Cash Runway
$4M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-12-01 | Phase2 Readout | — |
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07540338 | A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed ... | PHASE2 | Recruiting | 20 |
| NCT05834296 | Study in Subjects With Mild-to-Moderate Alzheimer's Dementia | PHASE2 | Active Not Recruiting | 30 |
| NCT06921590 | A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed ... | PHASE1 | Active Not Recruiting | 6 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.